Amarantus Bioscience Holdings IncOver The Counter Market:AMBS
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0001
- Day Range---
- 52 Week Range
- Volume70
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amarantus Bioscience Holdings Inc | 63.1K | 0.0x | --- |
Vioquest Pharmaceuticals Inc | 43.1K | 0.0x | --- |
Immunotech Laboratories Inc | 57.5K | 0.0x | --- |
Scopus Biopharma Inc | 46.3K | 0.0x | --- |
Adhera Therapeutics Inc | 64.3K | 0.0x | --- |
Poniard Pharmaceuticals Inc | 150.0 | 0.0x | --- |
Company Information
Amarantus Bioscience Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. It has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Company’s wholly owned subsidiary Cutanogen Corporation. The Company’s wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.
Contact Information
- Headquarters
- 655 Montgomery Street, Suite 900SAN FRANCISCO, CA, United States 94111
- Phone
- 408-737-2734
- Fax
- 408-852-4427
Executives
- President, Chief Executive Officer, Director
- Gerald Commissiong
- Chief Financial Officer, Interim Chief Operating Officer
- Barney Monte
- Chief Scientific Officer, Director
- John Commissiong
- Vice President - Operations, Controller, Treasurer, Secretary
- Marc Faerber
- Director
- Conn Flanigan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $63.1K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 630.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.17 |
EPS | $-3.49 |
Book Value | $-0.12 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
